NICE no for CML drugs follows Glivec price increase
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has said a preliminary "no" to Bristol-Myers Squibb's Sprycel (dasatinib), Novartis' Tasigna (nilotinib) and high-dose Glivec (imatinib) for treating chronic myeloid leukaemia (CML) that is resistant to standard-dose imatinib, because of what it said was weak evidence supporting the drugs' effectiveness and doubts about the economic models put forward. The "no" also follows an increase in the cost of Glivec.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.